Product Description
a selective, orally available irreversible small molecule tyrosine kinase inhibitor to Brutons tyrosine kinase and mutant epidermal growth factor receptor
Mechanisms of Action: ITK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Sorrento
Company Location:
Company Founding Year: 2006
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Small Cell Lung Cancer|Non-Small-Cell Lung Cancer
Phase 2: Non-Small-Cell Lung Cancer|COVID-19
Phase 1: Non-Small-Cell Lung Cancer|Lymphoma, B-Cell
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03060850 |
AC201602AVTN05 | P1 |
Unknown status |
Lymphoma, B-Cell |
2019-12-14 |
2021-01-06 |
||
NCT03053219 |
AC201606AVTN07 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2018-07-01 |
2019-03-21 |
Treatments|Trial Status |
|
NCT03001609 |
AC201606AVTN06 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2017-08-01 |
2019-03-21 |
Treatments |
|
NCT03574402 |
TRUMP | P2 |
Unknown status |
Non-Small-Cell Lung Cancer |
2022-12-30 |
2025-01-03 |
||
NCT02330367 |
AC201410AVTN02. | P2 |
Unknown status |
Non-Small-Cell Lung Cancer |
2022-12-01 |
2023-09-06 |
Primary Endpoints|Treatments|Trial Status |
|
NCT04528667 |
BTK-COV-202BR | P2 |
Completed |
COVID-19 |
2021-08-23 |
2021-11-04 |
||
NCT04440007 |
SOC | P2 |
Completed |
COVID-19 |
2021-07-01 |
2023-01-19 |
Patient Enrollment|Primary Endpoints|Treatments |
|
NCT03300115 |
AC201602AVTN03 | P2 |
Unknown status |
Non-Small-Cell Lung Cancer |
2019-06-17 |
2021-02-03 |
Primary Endpoints|Treatments|Trial Status |
|
NCT02274337 |
AC0010-phaseI | P2 |
Unknown status |
Non-Small-Cell Lung Cancer |
2017-06-01 |
2019-03-20 |
Treatments |
|
NCT03058094 |
AEGIS2:AC201602AVTN04 | P3 |
Withdrawn |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer |
2019-12-01 |
2019-03-21 |
Patient Enrollment|Treatments|Trial Status |